Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore.
Saved in:
| Title: | Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore. |
|---|---|
| Authors: | Chee CE; Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), National University Health System, Singapore, Singapore., Khara JS; Medical, Roche Singapore Pte Ltd, Singapore, Singapore., Cheong J; Market Access, Roche Singapore Pte Ltd, Singapore, Singapore., Fong J; Market Access, Roche Singapore Pte Ltd, Singapore, Singapore., Sivanesan S; Medical, Roche Singapore Pte Ltd, Singapore, Singapore., Choy JY; Market Access and Health Economics, Costello Medical Singapore Pte Ltd, Singapore, Singapore., Hu M; Market Access and Health Economics, Costello Medical Singapore Pte Ltd, Singapore, Singapore., Viswambaram A; Market Access and Health Economics, Costello Medical Singapore Pte Ltd, Singapore, Singapore., Toh HC; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore. |
| Source: | Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2024 Jun; Vol. 24 (5), pp. 631-641. Date of Electronic Publication: 2024 May 22. |
| Publication Type: | Journal Article; Comparative Study |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101132257 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8379 (Electronic) Linking ISSN: 14737167 NLM ISO Abbreviation: Expert Rev Pharmacoecon Outcomes Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1744-8379 |
|---|---|
| DOI: | 10.1080/14737167.2024.2319607 |
